Verseon starts dosing in clinical trial of anti-coagulant treatment

Writer, Stock Market Wire
Monday, February 4, 2019 - 09:57

Verseon said dosing had started in a clinical trial for its anti-coagulant treatment for the prevention of stroke and heart attack in coronary artery disease patients.

The phase I clinical trial was expected to continue dosing through the third quarter of 2019, with first results expected in the fourth quarter of the year.

At 9:57am: (LON:VSN) Verseon Corporation Plc share price was 0p at 100p


Related content

Verseon presents oral anti-coagulant treatment at Honolulu stroke conference

Clinical-stage pharmaceutical company Verseon said it presented its oral anti-coagulant treatment last week at the International Stroke Conference in Honolulu.

The company said it presented...

Mon, 11/02/2019 - 09:19


Verseon losses deepen on higher R&D, administrative spending

Pharmaceutical company Verseon posted a deeper first-half loss as it continued to develop its treatment prospects, including oral anticoagulants.

Pre-tax losses for the six months...

Wed, 08/08/2018 - 09:59


Verseon submits trial application for anticoagulant treatment

Verseon Corporation said it had submitted a clinical trial protocol in Australia for its anticoagulant treatment.

The proposed study was a double-blinded, randomized, placebo-controlled phase...

Wed, 18/07/2018 - 09:41


Verseon losses deepen slightly on increased R&D spend

Verseon Corporation, which offers a computer-driven platform to develop pharmaceuticals, posted a slightly deeper annual loss after it ramped up R&D spending.

Net losses for...

Mon, 25/06/2018 - 08:21


Small caps poised for big news in 2018

By the Shares team

Investors are spoiled for choice when it comes to small cap stocks with exciting events. As a taster for what’s to...

Thu, 21/12/2017 - 00:00